Healthcare / Medical Care FacilitiesHKSE
$2.40
+0.05 (+2.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $366.8M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.7%
↓Gross Margin
33.5%
↓Debt/Equity
0.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.9%
FCF CAGR
—
FCF margin
12.2%
FCF / Net income
-0.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.65B · net income $-976.1M · FCF $324.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.65B | $2.65B | $2.81B | $2.79B | $2.36B |
| Net Income | $-976.1M | $-976.1M | $283.1M | $344.7M | $121.1M |
| EBITDA | $-567.4M | $-567.4M | $725.6M | $828.6M | $486.2M |
| EPS | — | — | 0.10 | 0.12 | 0.05 |
| Gross Margin | 33.5% | 33.5% | 39.1% | 42.1% | 37.0% |
| Operating Margin | 7.9% | 7.9% | 16.1% | 18.4% | 10.7% |
| Net Margin | -36.8% | -36.8% | 10.1% | 12.4% | 5.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.31 | 0.31 | 0.25 | 0.25 | 0.48 |
| Current Ratio | 0.87 | 0.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $324.4M | $324.4M | $366.8M | $510.9M | $-417.7M |
| Returns | |||||
| ROE | -10.7% | -10.7% | 2.8% | 3.4% | 1.4% |
| Valuation | |||||
| P/E | — | — | 26.10 | 24.67 | 132.00 |
| EV/EBITDA | — | — | 12.62 | 12.10 | 41.49 |
| P/B | 0.69 | 0.69 | 0.69 | 0.80 | 2.00 |
| Growth & Yield | |||||
| Revenue Growth | -5.8% | -5.8% | 0.8% | 18.0% | — |
| EPS Growth | — | — | -16.7% | 140.0% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.10 → n/d
Residual
-10.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.